C81.01
Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck
Clinical Classification Guidelines
Medical Intelligence & Overview
Nodular lymphocyte predominant Hodgkin lymphoma (NLPHL) is a rare type of Hodgkin lymphoma, a cancer originating in the lymphatic system. Specifically classified with the ICD-10 code C81.01, this form of lymphoma primarily affects the lymph nodes located in the head, face, and neck. Unlike other types of Hodgkin lymphoma, NLPHL tends to grow slowly and often presents with localized lymph node swelling. Recognizing the characteristics of this disease helps in understanding its progression, diagnosis, and potential treatment options.
Causes & Symptoms
Clinical Causes: The exact cause of NLPHL remains unknown. It is believed to involve genetic mutations that lead to abnormal lymphocyte development. Environmental factors have not been conclusively linked, though immune system dysregulation may play a role. There is no clear evidence to suggest that lifestyle choices, such as smoking or diet, directly cause this lymphoma.
Key Symptoms: Painless swelling of lymph nodes in the head, face, or neck Breathlessness or cough if enlarged lymph nodes press on airways Persistent sore throat or feeling of fullness in the neck Unexplained weight loss over a period of time Fever, night sweats, or fatigue in some cases Recurrent infections or other signs indicating immune system involvement
Diagnostic & Treatment
Diagnosis Path: Diagnosing NLPHL involves a combination of clinical evaluation, imaging studies, and tissue sampling. Usually, the process includes: - Physical examination focusing on enlarged lymph nodes in the head, face, and neck. - Imaging techniques such as CT scans or PET scans to assess the extent of lymph node involvement. - Lymph node biopsy, where a small tissue sample is examined under a microscope to identify characteristic Reed-Sternberg cells and nodular lymphocyte patterns. - Immunophenotyping tests to confirm the presence of specific cell markers associated with NLPHL. - Additional blood tests to evaluate overall health and immune function.
Treatment Protocols: Treatment strategies for NLPHL are tailored to the individual based on the stage of the disease and overall health. Common approaches include: - **Radiation therapy**: Often used if the lymphoma is localized, targeting the affected lymph nodes. - **Chemotherapy**: Administered for more advanced or widespread cases; regimens typically involve drugs that target rapidly dividing cells. - **Immunotherapy**: Emerging treatments may include monoclonal antibodies that specifically target cancer cells. - **Watchful waiting**: In some cases, especially if the disease is slow-growing and asymptomatic, careful monitoring may be recommended. Management usually involves a multidisciplinary team to optimize patient outcomes and address potential side effects.
Clinical Advice & FAQs
Billing Guidance
Is C81.01 a billable ICD-10 code?
Yes, C81.01 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C81.01?
Clinical documentation must specify the nature of Nodular lymphocyte predominant Hodgkin lymphoma, lymph nodes of head, face, and neck and any associated comorbidities for accurate reporting.
Cite this Clinical Reference